Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr Ravi on the Use of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

August 18th 2023

Praful K. Ravi, MB, BChir, MRCP, discusses the use of prostate-specific membrane antigen-targeted therapies in metastatic castration-resistant prostate cancer, highlighting the use of the targeted radioligand lutetium Lu 177 vipivotide tetraxetan.

Dr Reichert on Novel Agents and Pathways Being Explored in Prostate Cancer

August 17th 2023

Zachery Roger Reichert, MD, PhD, discusses novel agents and pathways under exploration in prostate cancer.

Copper 64 PSMA I&T Meets Coprimary End Points of SOLAR Trial in Metastatic Prostate Cancer

August 15th 2023

Use of Copper 64 PSMA I&T for PET/CT imaging met the threshold for significance regarding region-level correct localization rate and patient-level correct detection rate in patients with histologically confirmed metastatic prostate cancer, meeting the coprimary end points of the phase 2 SOLAR trial.

Metastatic CRPC: Novel Treatment Strategies With Radioligand Therapy

August 15th 2023

Key opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.

Radioligands in the Treatment of Metastatic CRPC: Radium-223

August 15th 2023

Continuing their segment on radioligand therapy in metastatic castration-resistant prostate cancer, panelists highlight data behind use of radium-223.

Dr Alumkal on the Effects of the ARESENS Trial on the Treatment of mHSPC

August 14th 2023

Joshi Alumkal, MD, discusses the effects of the phase 3 ARESENS trial on the treatment of metastatic hormone-sensitive prostate cancer.

FDA Approves Niraparib Plus Abiraterone Acetate for BRCA+ mCRPC

August 11th 2023

The FDA has approved niraparib plus abiraterone acetate, given with prednisone, for the treatment of adult patients with deleterious or suspected deleterious BRCA-positive, metastatic castration-resistant prostate cancer, as detected by an FDA-approved test.

FDA Allows Continuation of Phase 1/2 Trial of ONCT-534 in mCRPC

August 11th 2023

The FDA has approved a study may proceed letter in advance of its 30-day review period to Oncternal Therapeutics for its phase 1/2 study evaluating ONCT-534, a novel dual-action AR inhibitor in patients with mCRPC who have relapsed or are refractory to approved AR signaling inhibitors.

Lack of Clinical Benefit Leads to End of Development for Etrumadenant in mCRPC

August 10th 2023

The development of etrumadenant as a potential treatment option for patients with metastatic castration-resistant prostate cancer will be discontinued after data from the phase 1/2 ARC-6 trial did not demonstrate a sufficient clinical benefit for etrumadenant plus zimberelimab and docetaxel compared with docetaxel alone.

Dr Vaishampayan on Patient Considerations When Choosing Between FDA-Approved Therapies in nmCRPC

August 8th 2023

Ulka Nitin Vaishampayan, MBBS, discusses patient factors to consider when choosing between apalutamide, enzalutamide, and darolutamide for the treatment of patients with non-metastatic castration resistant prostate cancer.

Radioligands in the Treatment of Metastatic CRPC: Lutetium-177–PSMA-617

August 8th 2023

Focused discussion on the role of lutetium-177–PSMA-617 as radioligand therapy in patients with metastatic castration-resistant prostate cancer.

Combination PARPi Strategies in Metastatic CRPC: Interpreting Data From Clinical Trials

August 8th 2023

Key opinion leaders in metastatic castration-resistant prostate cancer management review a subset of clinical trials focused on combination strategies with PARP inhibitors.

Dr Sieber on the Importance of Evaluating Comorbidities in Prostate Cancer Prior to ADT

August 3rd 2023

Paul Sieber, MD, discusses the importance of evaluating comorbidities in patients with prostate cancer, including assessing risk factors for cardiovascular events in those who are initiating androgen deprivation therapy.

Advent of PARP Inhibitors in Metastatic CRPC

August 1st 2023

Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.

Evolving Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer

August 1st 2023

Comprehensive insight to key treatment modalities for patients with nonmetastatic castration-resistant prostate cancer and how to select amongst them.

Dr Wise on Key Trials Establishing Treatment Intensification as a SOC in mHSPC

July 31st 2023

David R. Wise, MD, PhD, discusses key trials establishing the benefit of hormone therapy– or chemotherapy-based doublet therapy for patients with metastatic hormone-sensitive prostate cancer

Analysis Helps Distinguish the Molecular Profile of Intraductal Carcinoma of the Prostate

July 31st 2023

Benjamin Miron, MD, explains the purpose of studying the molecular profile of intraductal carcinoma of the prostate, expands on the potential prognostic and targetable alterations identified in patients with this histology, and discusses the planned cohort expansion and analysis of RNA signatures in this population.

EU Approves Piflufolastat (18F) PSMA PET Imaging Agent for Prostate Cancer

July 28th 2023

The European Commission has approved piflufolastat (18F) for the detection of prostate-specific membrane antigen–positive lesions with positron emission tomography in adults with prostate cancer.

Dr Agarwal on Future Questions to Address Following the TALAPRO-2 Trial in mCRPC

July 26th 2023

Neeraj Agarwal, MD, discusses future questions to be addressed following the phase 3 TALAPRO-2 trial evaluating the combination of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Gaps in Validated Quality Indicator Use Are Evident in Active Surveillance of Low-Risk Prostate Cancer

July 26th 2023

Varied levels of compliance were observed in terms of using validated quality indicators to determine the quality of active surveillance for patients with low-risk prostate cancer, according to findings from a population-based study published in the Journal of the Comprehensive Cancer Network.